

May 21, 2003

PhilHealth Circular

No. 19, s. 2003

TO

ALL HEALTH CARE PROVIDERS, CLAIMS PROCESSING

DEPARTMENTS - NATIONAL CAPITAL REGION AND PHILHEALTH REGIONAL OFFICES AND ALL OTHER

CONCERNED

SUBJECT:

PHILHEALTH OUTPATIENT ANTI-TUBERCULOSIS/

DIRECTLY OBSERVED TREATMENT SHORT-COURSE

(DOTS) BENEFIT PACKAGE

Pursuant to PhilHealth Board Resolution Numbers 485 and 490, s-2002 and in order to accomplish its mandate of providing accessible quality health care services to all its members, an Outpatient Anti-tuberculosis or Directly Observed Treatment Short-course (DOTS) Benefits Package shall be included in PhilHealth's Benefits Package. The following are the guidelines to avail of this package:

A. BENEFIT

- 1. A flat rate of 4,000 pesos per case shall be paid to an accredited DOTS facility and this amount shall be given in two separate payments.
- 2. For this fee, the provider shall cover diagnostic work-up, consultation services and anti-TB drugs the patient requires in an outpatient set-up.
- 3. The first payment of 2,500 pesos shall be paid after the accredited DOTS center has completed the intensive phase of DOTS treatment. The end of the intensive phase shall be considered as the date of treatment.
- 4. The final payment of 1,500 pesos shall be paid to the DOTS center after the end of maintenance phase. The end of the maintenance phase shall be considered as the date of treatment.
- 5. Payment to referral centers, physicians and other health care workers shall be settled by the referring DOTS Center.
- 6. The Corporation shall not pay for additional services rendered or for an extension of treatment.

7. All claim applications of accredited DOTS Centers shall also be covered by the rules on ICD-10 requirements by the Corporation.

B. ELIGIBILITY:

- 1. All members and qualified dependents of the National Health Insurance Program (NHIP) who satisfy the criteria of benefit eligibility and are not disqualified by the exclusion criteria may avail of the DOTS Benefit Package.
- 2. The DOTS Benefits Package is designed for new cases of pulmonary and extrapulmonary tuberculosis for children and adults.

New Case - A patient who has never had treatment for TB or who has taken antituberculosis drugs for less than one month.

- 3. However, PhilHealth shall not cover the following TB cases:
 - a. Failure case A patient who, on previous treatment, is sputum smear positive at five months or later during the course of treatment.
 - b. Relapse case- A patient previously treated for tuberculosis who has been declared cured or treatment completed, and is diagnosed with bacteriologically positive (smear or culture) tuberculosis.
 - c. Return after default (RAD) case A patient who returns to treatment with positive bacteriology (smear or culture), following interruption of treatment for two months or more.
- 4. A beneficiary shall be entitled to avail of the DOTS package if the following conditions are met:

Type of Membership	Eligibility
Employed Individually Paying Program (IPP)	Three (3) months of contributions must have been paid within immediate six (6) months prior to enrollment at the DOTS Center.
Sponsored (Indigent) Pensioner Overseas Filipino Worker	Enrollment at the DOTS Center shall start within the date of effectivity of membership as stated in the ID Card/Eligibility Certificate.

In addition, all PHIC beneficiaries, regardless of type of membership, should have their monthly premium paid during the duration of DOTS treatment.

C. REIMBURSEMENT PROCESS

- 1. All accredited DOTS centers shall submit a copy of NTP Treatment Card (see attached) of enrolled PhilHealth beneficiaries or register them to the TB Management Information System of the Quality Assurance Research and Policy Development Group (QARPDG) within sixty (60) days of patient's enrolment to the program.
- 2. A copy of updated NTP Treatment Card, together with the DOTS Claim Form (see attached), must be submitted within sixty (60) days upon completion of each treatment phase (intensive and/or maintenance phase) to the Claims Department at the Central Office or the PhilHealth Regional Office.
- 3. Payment of DOTS centers shall be made within sixty (60) days upon submission of complete requirements.
- 4. Claims with incomplete requirements shall be returned to the health facility and must be complied within sixty (60) days from date of receipt of notice. Failure to comply shall cause denial of the claim.

D. PROVIDERS

- 1. The providers of the DOTS benefits package shall be outpatient clinics duly accredited by PhilHealth.
- 2. To ensure technical capability of health care providers, only facilities duly certified by the Philippine Coalition Against Tuberculosis (PhilCAT) may apply for accreditation.
- 3. Accreditation of DOTS facilities is prospective. All claims of DOTS facilities wherein the intensive phase were completed prior to the accreditation of the DOTS facilities shall not be compensated.
- 4. All accredited providers are expected to have computers and access to the Internet to ensure compliance with electronic patient registration requirements of this benefit.

E. EFFECTIVITY

1. This new package shall take effect for all DOTS care provided in PhilHealth-accredited facilities where the date of treatment of the intensive phase is on or after May 21, 2003.

All other issuance not inconsistent with this circular shall remain in full force and effect. For your information and guidance.

FRANCISCO T. DUQUE, MD, MS

President and CEO

										- 17		•	. •	~	110	nt	0	aı c	3														
TE	3 CA	SE	NUM	IBEF	₹			DA		THE	CA	RD I		\top		RE	GIÓN	181	'nO	VIÑ] <u> </u> -			si (S)	жні	JHO	SP./	OTE	ERS	5			
1									- 1	OPE	NEC)																					
						Ì		M	anth	da		V03F																					
NAME	OF F	ATI	ENT					1411	<u> </u>	ua.	· <u>y</u>	year			ÖÖC	up.	TÏÖ	N					1 4	AGE.	[9	SEX		ïŵ	EIG	ΗŤ			
man di i Ciletti											OCCUPATION AGE										M / F		1		kg								
4555									, -				=:=		. ها داد د				· -				. !					<u></u>					
ADDRESS NAME/RELA											OITA	TIONSHIPS/ADDRESS (CONTACT PERSON)									i	No. of House Hold											
DDE\//	Niie	TD -	TÖE	A 784	ENIT																					Contacts: BCG SCAR							
PREVIOUS TB TREATMENT: []No []Yes																							BCG SCAR										
Duration: [] less than 1 mo. [] more than 1 mo.). Sp	. Specify drugs:										[] Doubtful										
When: Where:											<u></u>										'	1 -											
	CLASSIFICATION OF TB:											CATEGORY (encircle):																					
[] PUI	LMO	NAF	RY MA	MAG	1V .:	.							I. 6-SCC (2HRZE/4HR))						
[] EX	I KA	PUL	-MQ	NAN	(7.5)	te:_					-				v ca: Sme		1									2. FAILURE FTER DEFAULT (RAD)							
TYPE (F P	ATIE	NT:												Seri								THE					•	(,			
[]NEV						AFT	ER (DEFA	AUL.	T (R	AD)				. Sm				FA				C (21										
[]REL	APS	E	[]F	AIL	JRE											dìog				1			v Ca			·							
[]TRA	NS.	IN [[][THE	R									2.2	. Ext	tra-p	ulm	onar	У				Sme										
																						2.	Ext			onar Isly i							
SPUTU	M E	XAM	IINA	TIOI	N RE	SUL	TS		—				TF	REA	ТМЕ	NT S	TAF	RTE	D:	14 100				J. 30	., .	. <u>y</u>							
Month		Due	Dat	e				nine	d	F	Resu	lt	1	moi	nth_		day		y	ear_													
0		1.78° 4'14,		(3)									TF	REA	TME	NT (OUT	COM	IE:		- 	···				_							
2] .															_					
3_														CU		,					[REA			FAIL	.URE	=					
4	_												- ,	uat TD	e:_/ EAT	MEN	īīc	OME) E1	ED	ſ	ום ו	ate:_	m'- -	ËD								
5 6	+												՝	Dat	e:_/	/	• • •	OWIT	LL	כט	L		ate:_										
>7	+												┤ 【	DIE	ED								ecif						_				
									1	Date:/_/_ [] TRANSFER																							
REMAR	REMARKS:													Date	e:_/	<u>_</u> /					Į					UI							
REMAR	(NS:													Cau	e:/ ise:_	_′					Į.	Da	ate:_	1_1		UI							
REMAR	(1/5:													Cau	e:/ ise:_ 						-	Da Sp		.//. y:									
								~			·····			Cau	:se:_							Da Sp	ate:_ occlf	_// y:									
														Cau	:se:_							Da Sp	ate:_ occlf	_// y:						·			
								~						Cau	:se:_							Da Sp	ate:_ occlf	_// y:						 			
Nam	ne of	Tre	atm	ent F	Partr	ner:_		~						Cau	:se:_							Da Sp	ate:_ occlf	_// y:						<u></u> 			
	ne of	Tre	atm	ent F	Partr	ner:_		~						Cau	:se:_							Da Sp	ate:_ occlf	_// y:						 -			
Nam	ne of	Tre	atm	ent F	Partr	ner:_		~			11	12		Cau	:se:_							Da Sp	ate:_ occlf	_// y:						- 30	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ne of	Tre	atmo	ent f	Partr	ner:_ se)]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ntak	Tre	atme	sive	pha 5	se)	7]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ntak	Tre	atme	sive	pha 5	se)	7]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ntak	Tree (Ir	atme	sive	pha 5	se)	7]			Cau	ise:_		0	esig	ınati	on:_		St Ds	ate:_ pecif	_//. y: 						-	31		
Nam Drug I	ntak	Tre	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug I	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			
Nam Drug i	ntak	Tree (Ir	atmo	sive	pha 5	se)	7 7 5e)	8	9	10	11	12	13	14	15	16	17	18	nati	on:	21	22	23	/ / y:	25	26	27	28	29	30			

PHILHEALTH TB-DOTS PACKAGE

•	(DATE RECEIVED)	

March 2003	CLAIM FORM 5							
NOTE: THIS FORM TOGETHER WITH CLAIM FORM 4 SHOULD BE FILED W	TTH PHILHEALTH WITHIN SO GALENDAR DAYS FROM DATE OF CO.	MPLEYION OF TREATMENT						
PhilHealth Accreditation No.								
2. Name of Hospital/DOTS Center								
3. Address of Hospital/DOTS Center								
No., Street Municipality/City	Barangay Province	Zip Code						
4. Name of Member								
Last Name First Name	PIN							
								
5. Address of Member No., Street	Barangay							
Municipality/City	Province	Zip Code						
6. Name of Patient Last Name		te of Registration Enrollment: Ompletion of:						
First Name		intensive phase date of death						
Middle Name		maintenance						
		manuerance						
10. Diagnosis and ICD-10 Code:								
11. CLASSIFICATION OF TB:	12. CATEGORY (tick box):	2C0/CUDEN						
Pulmonary Extra-Pulmonary site:	I. 6-SCC (2HRZE/4HR) II. 8-CC (2HR New Case 1. Relaps	se 2.Failure						
TYPE OF PATIENT:	1, Smear (+) 3. Retur 2, Seriously ill III. 6-SCC (2H	n After Default (RAD) 4. Other (smear +) RZ/4HR)						
New Return After Default (RAD) Relapse Failure	2.1. Smear (-): MA or FA New Ca. Radiographic lesion 1. Smea	se r (-): Minimal						
Trans. In Other		pulmonary not seriously ill						
13.CERTIFICATION of HOSPITAL/DOTS CENTER: I certify that the services rendered are duly recorded in the patient's chart and that the information in this form are true and correct.								
in the bue and conect.								
Signature Over Printed Name of Authorized Repre	sentative Date Signod	Official Capacity						